This was a multi-center retrospective analysis of patients with renal cell carcinoma (cT1-3aN0M0) from 1987-2016. After initial comparison of outcomes between pT1, pT2 and pT3a, patients were sub-stratified within the pT3a category based on presenting clinical stage. The pT1, pT2 and the subdivided pT3a group (cT1 → pT3a, cT2 → pT3a, and cT3a → pT3a) were analyzed and compared. Primary outcome was recurrence free survival (RFS). Secondary outcome was overall survival (OS).
2,640 patients were analyzed (2,125 cT1, 448 cT2, and 67 cT3a, mean follow up 67.8 months). Rate of incidental T3a upstaging from cT1-2 was 14.7%. Compared to pT1-2 disease, patients with incidental pT3a upstaging had higher rate of recurrence (7.5% vs. 29.6%, p < 0.001) and all-cause mortality at last follow up (15.9% vs. 25.4%, p < 0.001). With regards to RFS, when pT3a was subdivided based on presenting clinical stage, significant differences in RFS emerged which aligned differently. Compared to 5 year RFS of pT1 (94.4%), cT1 → pT3a aligned with pT2 (76.6% and 81.2%, p = 0.346) while cT2 → pT3a aligned with cT3a → pT3a 47.4% and 44.0%, p = 0.815). With regards to OS, a similar alignment was noted for 5 year OS after subdivision, where pT1 was 89.9%, while cT1 → pT3a correlated with pT2 (79.8% and 83.1%, p = 0.640) and cT2 → pT3a correlated with cT3a → pT3a 67.0% and 64.2%; p = 0.893).
Patients with cT1 upstaging to pT3a have outcomes more similar to pT2, than patients with cT2 upstaging to pT3a, which align more closely to cT3a patients upstaging to pT3a. Future refinements of the TNM staging system for RCC should consider re-grouping cT1 upstaging to pT3a into the pT2 group.
Presented by: Zachary Hamilton, San-Diego, CA, USA
Co Authors: Umberto Capitanio, Deepak K. Pruthi, Ahmet Bindayi, Alessandro Larcher, Stephen Ryan, Madhumitha Reddy, Kendrick Yim, Aaron Bloch, Charles Field, Sean Berquist, Eric Ballon-Landa, Michael Liss, Thomas B McGregor, Francesco Montorsi, Ithaar Derweesh; Saint Louis University, St Louis, MO; Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy; UT San Antonio, San Antonio, TX; University of California San Diego, San Diego, CA; University of Manitoba, Winnipeg, MB, Canada
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA